<DOC>
	<DOCNO>NCT00038844</DOCNO>
	<brief_summary>Objective low-dose transplant regimen must produce follow effect : 1 . Suppression patient 's immune system prevent rejection donor cell ; 2 . Control lymphoma . The pretransplant regimen must suppress lymphoma sufficiently prevent mark progression tumor allow time GVT effect occur .</brief_summary>
	<brief_title>Safety Efficacy Campath Nonmyeloablative Transplantation</brief_title>
	<detailed_description>Alemtuzumab drug specifically attack type leukemia lymphoma cell . In addition , suppress patient ' immune system , therefore help prevent rejection donor marrow stem cell . Before treatment start , patient physical exam , include blood test ( 100 - 120 cc ) urine test . Women able child pregnancy test . Bone marrow sample take . Patients chest x-ray , CT scan EKG , test lung function . Blood test ( 100 - 120 cc ) marrow sample , x-rays do need track effect transplant . For bone marrow sampling , large needle place numbed hipbone . The bone marrow withdrawn needle . Patients transfusion blood platelet need . Blood test ( 100 - 120 cc ) do daily patient hospital . Alemtuzumab inject patient 's vein . This do 3 day row ( day 1 3 ) . The drug diphenhydramine ( Benadryl ) acetaminophen ( Tylenol ) give prevent ease side effect . Patients also receive fludarabine cyclophosphamide daily 3 day . They give day alemtuzumab . Rituximab give ( patient , base subtypes lymphomas ) eight day transplant weekly total 4 dos . All chemotherapy drug give catheter ( plastic tube ) extend large chest vein . The catheter leave place throughout treatment . When chemotherapy finish , blood stem cell donor give catheter . G-CSF , growth factor promote production blood cell , injected skin day neutrophil count recover blood . A `` boost '' donor cell ( lymphocyte ) give 3 month transplant disease get bad DNA test blood show lymphocytes blood donor . These cell give vein , without chemotherapy , clinic . Treatment give hospital M. D. Anderson . Patients need stay hospital 3 4 week . Patients take study disease progress . Patients must stay Houston area 100 day transplant . After , patient need return Houston time time blood test , urine test , exams . This investigational study . The FDA approve drug use study . Their use together study investigational . About 100 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Up 70 year age ( physiological ) . 2 . Any histological subtype lymphoid malignancy ( CD20 negative disease receive Rituximab ) . 3 . Patients relapse partial remission stable disease . 4 . Patients fail prior autologous transplant also eligible . 5 . Patients must match unrelated donor human leukocyte antigen ( HLA ) identical sibling available . Point scale ( PS ) &lt; 2 . 6 . Patients include even previously expose Campath Rituximab . 1 . Past history anaphylaxis follow exposure rat mousederived CORgrafted humanize monoclonal antibody . 2 . Less 4 week since prior chemotherapy count 1st day treatment regimen . 3 . Pregnancy lactation . 4 . HIV HTLVI positively . 5 . Serum creatinine &gt; 1.6mg/dl serum bilirubin &gt; 1.5mg/dl unless due tumor . 6 . Pulmonary function test ( PFTs ) OLCO &lt; 50 % , cardiac EF &lt; 50 % predicted level . 7 . Patient severe concomitant medical psychiatric illness .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Campath-1 H</keyword>
	<keyword>Campath</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Rituximab</keyword>
</DOC>